AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 231 min read$AIM

Equels Thomas K purchased $5K of AIM

Equels Thomas K (CEO & President) purchased 31,250 shares of AIM ImmunoTech Inc. (AIM) at $0.16 on 2026-10-22.

Original reporting
SEC EDGAR · Equels Thomas K
Published Oct 23, 2026, 4:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 4:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AIM
Bullish
high confidence
Mentioned
$AIM
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AIMBullishLow
01

Why it matters

The disclosed purchase adds a modest positive signal but is unlikely to move the stock significantly.

02

Market read

Primary insider purchase with limited market impact; relevant mainly to AIM investors.

03

What to watch

Potential upcoming clinical milestones not disclosed may be the real driver of insider confidence.

Relevance 4/10Novelty 3/10Timing: today

Background

Form 4 filing reveals insider transaction for AIM ImmunoTech, a micro‑cap biotech.

Company-level read

Ticker impact

$AIMBullishHigh confidence
Context

CEO Equels Thomas K bought 31,250 shares of AIM at $0.163 per share, a $5,094 purchase disclosed on Form 4.

Expected impact

modest upward pressure as market prices in insider confidence

Evidence & confidence

The purchase is small relative to market cap but signals insider belief in the stock, likely prompting short‑term buying interest.

Market effects

Sector

Minimal impact on biotech sector; insider activity is routine.

Regional

No broader regional effect.

Global

Limited to AIM shareholders.

Counterpoint

What could challenge this read

The purchase is too small to affect price; could be routine compensation.

Key entities

  • company
    AIM ImmunoTech Inc.

    Biotech company listed on NASDAQ under ticker AIM.

  • person
    Equels Thomas K

    CEO and President of AIM ImmunoTech.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AIM insider trading history →

Related articles

OCT 7
$AIMMedAI 8/10

Exploratory data found 34.8 months’ median survival in 39 patients with a low blood-cell ratio.

AIM ImmunoTech highlighted exploratory data showing 34.8 months' median survival in 39 pancreatic cancer patients with low neutrophil-to-lymphocyte ratio. Final dosing is complete in the DURIPANC trial with AstraZeneca's Imfinzi, but endpoint reporting is pending. The company is pursuing further clinical development and partnerships for a Phase 3 study.

stocktitan.net2 min
AUG 10
$AIMLow

AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3…

AIM ImmunoTech Inc. (AIM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CONFIDENTIAL DRAFT NOT FOR IMMEDIATE RELEASE AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer Completed Enrollment and Ampligen Do

SEC EDGAR 8-K2 min
JUL 23
$AIMMedAI 8/10

AIM Stock Soars 42% As Pancreatic Cancer Trial Hits Key Enrollment Milestone Before Schedule — CEO Sees 'Significant Value-Inflection Period' Ahead

AIM ImmunoTech said its Phase 2 pancreatic cancer trial of Ampligen (rintatolimod) plus AstraZeneca’s Imfinzi (durvalumab) after FOLFIRINOX reached final patient enrollment ahead of schedule. The company expects to complete dosing and assess the primary Clinical Benefit Rate endpoint in December 2026, while continuing Phase 3 planning and expanding regulatory and IP efforts.

stocktwits.com4 min